ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / KMDA / earnings
CRMD (59) BLSM (42) PRTA (23) PHAT (33) ⌘ Pro Terminal →

Kamada Ltd. (KMDA) Next Earnings Date & Expected ±5.3% Move

$7.36 -4.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.29

Kamada Ltd. (KMDA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $444.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KMDA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kamada Ltd. (NASDAQ: KMDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $7.36 (-4.42% 1D, market cap $444.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KMDA ranks #334 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KMDA compare to CRMD and BLSM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KMDA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRMD (CorMedix Inc.) holds a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KMDA?
▼

For Kamada Ltd. (KMDA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #334 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.29 (-0.99%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (12)Whales (5)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$10 Bull$7 Base$5 Bear
📬 FREE KMDA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KMDA)Realized 20D OHLCV Swing Band: ±5.3%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY KMDA SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($12.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$7.69+2.1% Next Q
Q2 (-2Q)
51
Grade C-$7.85+2.5% Next Q
Q3 (-1Q)
49
Grade D$8.05-8.6% Next Q
Current
46
Grade D$7.36-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KMDA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KMDA currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.17) and Max Pain ($7.73) forces dealer call-delta covering toward $9.82.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KMDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KMDA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±5.3% Swing Band

±$0.39 Expected Swing
$6.97 (-5.3%)Spot $7.36$7.75 (+5.3%)
MODEL EARNINGS SETUP GAUGE

KMDA Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (46/100)Model Risk Weight (54/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KMDA)

  • ✓Walkthrough of KMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KMDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.22%📐 HORIZONTAL RANGE
2026-11-03O $7.95H $7.95L $7.36C $7.36VOL 47.5K
RES: $9.72SUP: $6.63SMA50: $8.17SMA200: $8.02
$9.11$8.50$7.88$7.27$6.66RES $9.72SUP $6.63$7.362026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KMDA Butterfly Map → + Track KMDA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KMDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KMDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KMDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KMDA)

Health Care Rank #334 of 1016 ⚔️ CRMD vs KMDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KMDA vs. CRMD, BLSM, PRTA, PHAT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kamada Ltd. (KMDA) ranks #334 by composite RQD confidence (46/100, grade D) and #462 by equity capitalization ($444.4M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with KMDA at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KMDA ACTIVE
Kamada Ltd.
D 46/100 — — — -4.42% $444.4M Benchmark Subject
CRMD
CorMedix Inc.
C- 59/100 3.7x 88.5% 45.5% -5.36% $443.9M /crmd-vs-kmda →
BLSM
BlossomHill Therapeutics Inc.
D- 42/100 — — — -9.67% $437.0M /blsm-vs-kmda →
PRTA
Prothena Corporation plc
E 23/100 — — -35.0% -2.12% $434.8M /prta-vs-kmda →
PHAT
Phathom Pharmaceuticals Inc.
E 33/100 — 87.1% -35.0% +3.05% $466.6M /phat-vs-kmda →

2. KMDA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Kamada Ltd. (KMDA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $444.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. KMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kamada Ltd. (NASDAQ: KMDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $7.36 (-4.42% 1D, market cap $444.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KMDA ranks #334 in composite RQD confidence.

How does KMDA compare to CRMD and BLSM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KMDA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRMD (CorMedix Inc.) holds a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KMDA?

For Kamada Ltd. (KMDA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #334 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KMDA trading relative to its 50-day, 200-day, and 52-week technical levels?

KMDA last traded at $7.36 (-4.42% on volume of 168,909 shares), positioning the stock -9.91% below its 50-day simple moving average ($8.17) and -8.23% below its 200-day simple moving average ($8.02). Across its 52-week range of $6.55 to $9.35, KMDA sits at the 28.9% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±5.3% ($6.97 to $7.75).

Direct Sub-Reports: KMDA RQD Cockpit KMDA 12M Forecast KMDA Earnings & Move KMDA Dividends & DRIP KMDA Insiders & 13F KMDA Whale Options KMDA Profit Sankey KMDA News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KMDA — Kamada Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:06Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

KMDA scores 49 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are as follows:

  • Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). The rating's cash-generation pillar is weak, and the source data shows no measured return on invested capital or free cash flow yield. For a prospective investor, this means the business is not currently demonstrating the cash-earning power that typically supports valuation.
  • Whale 13F Flow: 8 / 20 (institutional accumulation and options positioning). This is a below-midpoint reading, suggesting limited evidence of large institutional conviction in the source data.
  • Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The reading indicates modest insider-side confidence signals.
  • Macro Regime Fit: 7 / 20 (beta 1.0; sector sensitivity). A beta of 1.0 means the stock is rated as moving in line with the broader market, and the low pillar score signals weak positioning for the prevailing regime per the rating.
  • Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; debt/equity 0.5). This is the strongest pillar, indicating the balance sheet is comparatively the most defensible part of the thesis.

Taken together, the rating frames KMDA as a name where the balance sheet offers some stability, but cash generation, institutional support, and insider signals are not supportive.95 price. This is an educational summary of the rating, not personalized advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kamada Ltd. (KMDA) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.5B. Products, customer base, and revenue model are —

Per the market data, gross margin, operating margin, and net margin are each 0%, and ROIC and FCF yield are each 0%. The forensic balance sheet pillar reports an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a debt/equity ratio of 0.5.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case: The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, debt/equity 0.5) is the rating's strongest component and provides a defensible base. With Fundamental Cash Engine at 12/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $6.55 – $9.35 52-week range.
  • 🐻 Primary Bear Case: Cash generation is nil on the source data (ROIC 0%, FCF yield 0%), and the rating assigns weak institutional and insider scores (8/20 and 9/20). Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are —

  • Key Question #1: What are the company's specific products, approved indications, and key biosimilar programs referenced in the Stifel note?
  • Key Question #2: What is the outcome of the November 9, 2026 earnings and management call?
  • Key Question #3: What is the analyst consensus rating and price target distribution, and who are the major institutional or insider holders?

KMDA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kamada Ltd. (KMDA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KMDA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KMDA Bull vs. Bear Conversation Board — What's Your Call at $7.36?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KMDA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KMDA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue Fundamental Long-Only 🐂 BULLISH 🎯 Target: $10.09 (+31.0%)
📌 Pinned Debate

The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, debt/equity 0.5) is the rating's strongest component and provi

Don't sleep on KMDA's setup in Health Care. The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, debt/equity 0.5) is the rating's strongest component and provides a defensible base.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (46/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $6.62 (-14.0%)
Spot @ $7.70

Valuation & margin reality check on KMDA at $7.70 before chasing here

Fading this rally in KMDA at $7.70. Valuation & margin reality check on KMDA at $7.70 before chasing here. With a beta of 1.0 and the stock sitting at $7.70 (52-wk range $6.55–$9.35), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%